ClinicalTrials.gg
TerminatedNCT00273338Updated Nov 6, 2007

DN-101 in Combination With Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (AIPC Study of Calcitriol Enhancing Taxotere [ASCENT-2])

A Phase 3 interventional study of calcitriol and docetaxel in Prostate Cancer, sponsored by Novacea. Terminated at 223 sites in 9 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2007-11-06.

Sponsored by Novacea · Phase 3, Interventional, and Treatment

Why this study was terminated
DSMB

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,200
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 15 studies testing calcitriol in Prostatic Neoplasms — none open to participants now, none under way, none of them phase 3. Calcitriol · Prostatic Neoplasms.

Planned enrollment
Largest of 14
1,200 · median 21
Started
2006
with 3 others
Phase 3
Only one
of the 15
Registered
10th of 15
by date
Lead sponsor
3 of 15
Novacea

Among the 15 studies testing calcitriol in Prostatic Neoplasms, this one has the largest planned enrollment of the 14 interventional ones that give a count, is one of 4 that started in 2006, is the only one in phase 3, and was the 10th registered.

Prostatic Neoplasms

7,053 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

None of the 15 studies testing calcitriol in Prostatic Neoplasms is open now. The open studies under Prostatic Neoplasms, anywhere →

About calcitriol

Calcitriol: first FDA approval 1978 (ROCALTROL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,233 Prostatic Neoplasms studies recruiting now, 931 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 15 studies testing calcitriol in Prostatic Neoplasms as a file.
02

Study summary

The primary objective of this study is:

  • To evaluate the effect of DN-101 in combination with docetaxel (ASCENT regimen) on survival in metastatic androgen-independent prostate cancer

The secondary objectives of this study are:

  • To determine the effect of the ASCENT regimen on the rate of thromboembolic events (blood clots)
  • To determine the effect of the ASCENT regimen on prevention of skeletal-related events (fractures)
  • A Separate sub-study will be conducted at selected study sites in North America to determine the population PK of DN-101.
03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • Androgen-independent Prostate Cancer (AIPC)
  • Prostate Cancer
  • DN-101
  • calcitriol
  • Taxotere
  • docetaxel
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histopathologically or proven adenocarcinoma of the prostate
  • Documented prostate adenocarcinoma
  • Documented progression while on androgen ablation therapy detected by rising prostate specific antigen (PSA) and/or imaging
  • Age >= 18 years
  • (ECOG) performance status \<= 2
  • Adequate hematologic, renal and hepatic function
  • >= 3 months

Exclusion criteria

Exclusion Criteria:

  • Prior chemotherapy, except estramustine
  • Prior chemotherapy with docetaxel
  • Prior isotope therapy (e.g., strontium-89, samarium-153, etc.)
  • One or more to the use of
  • History of cancer-related hypercalcemia
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,200 participants (estimated)

Interventions

06

Study locations

223 sites
  • Birmingham Hematology & Oncology Associates, LLC
    Birmingham, Alabama 35223, United States
  • Northwest Alabama Cancer Center
    Muscle Shoals, Alabama 35661, United States
  • Alaska Clinical Research Center
    Anchorage, Alaska 99508, United States
  • Hematology Associates - AOA
    Phoenix, Arizona 85012, United States
  • Premiere Oncology of Arizona
    Scottsdale, Arizona 85260, United States
  • Northern Arizona Hematology & Oncology Associates, AOA
    Sedona, Arizona 86336, United States
  • Southern Arizona VA Healthcare System
    Tucson, Arizona 85723, United States
  • U of Arizona / Arizona Cancer Center
    Tucson, Arizona 85724, United States
  • Genesis Cancer Center
    Hot Springs, Arkansas 71913, United States
  • Tower Cancer Research Foundation
    Beverly Hills, California 90211-1850, United States
  • Pacific Shores Medical Group
    Long Beach, California 90813, United States
  • The Angeles Clinic and Research Institute, Inc.
    Los Angeles, California 90025, United States
  • UCLA department of Urology
    Los Angeles, California 90095-1738, United States
  • Veterans Affairs Northern California Health Care System
    Martinez, California 94553, United States
  • Sutter Gould Medical Foundation
    Modesto, California 95355, United States
  • Monterey Bay Oncology
    Monterey, California 93940, United States
  • Comprehensive Cancer Center at
    Palm Springs, California 92262, United States
  • Sutter Cancer Center
    Sacramento, California 95816, United States
  • UCD Cancer Center-Clinical Trials
    Sacramento, California 95817, United States
  • Sharp Memorial Hospital
    San Diego, California 92123, United States
  • California Pacific Medical Center
    San Francisco, California 94115, United States
  • Stanford University
    Stanford, California 94305, United States
  • Rocky Mountain Cancer Centers
    Colorado Springs, Colorado 80909, United States
  • Georgetown University Lombardi Cancer Center
    Washington, District of Columbia 20007, United States
  • Pasco Hernando Oncology Associates, P.A.
    14529 Cortez Blvd., Florida 34613, United States
  • North Broward Medical Center
    Deerfield Beach, Florida 33064, United States
  • Florida Cancer Specialists
    Fort Myers, Florida 33901, United States
  • Broward Oncology Associates
    Ft. Lauderdale, Florida 33308, United States
  • Michael and Dianne Bienes Comprehensive Cancer Center
    Ft. Lauderdale, Florida 33308, United States
  • Gainesville Hematology Oncology Associates
    Gainesville, Florida 32605, United States
  • University of Florida Shands Cancer Center
    Gainesville, Florida 32611, United States
  • Integrated Community Oncology Network
    Jacksonville, Florida 32256, United States
  • Sylvester Comprehensive Cancer Center, U of Miami
    Miami, Florida 33136, United States
  • Innovative Medical Research of South Florida Inc.
    N. Miami Beach, Florida 33179, United States
  • Pasco Hernando Oncology Associates P.A.
    New Port Richey, Florida 34652, United States
  • Florida Cancer Institute
    New Port Richey, Florida 34655, United States
  • Ocala Oncology Center
    Ocala, Florida 34474, United States
  • Cancer Centers of Florida, P.A.
    Ocoee, Florida 34761, United States
  • AYS Urology
    Trinity, Florida 34655, United States
  • Phoebe Cancer Center
    Albany, Georgia 31701, United States
  • Northeast Georgia Cancer Care, LLC
    Athens, Georgia 30607, United States
  • Peachtree Hematology-Oncology Consultants, PC
    Atlanta, Georgia 30309, United States
  • Atlanta Cancer Care
    Atlanta, Georgia 30342, United States
  • Northeast GA Medical Center
    Gainesville, Georgia 30501, United States
  • Georgia Cancer Specialist
    Tucker, Georgia 30084, United States
  • South Georgia Medical Center
    Valdosta, Georgia 31602, United States
  • Hematology Oncology Associates of Illinois
    Chicago, Illinois 60611, United States
  • Midwest Prostate & Urology Health Center
    Chicago, Illinois 60640, United States
  • Cancer Care & Hematology Specialists of Chicagoland
    Niles, Illinois 60714, United States
  • Oncology Specialists
    Park Ridge, Illinois 60068, United States
  • Swedish American Regional Cancer Center
    Rockford, Illinois 61104, United States
  • Hematology Oncology Associates of Illinois, L.L.C
    Skokie, Illinois 60077, United States
  • Central Indiana Cancer Centers
    Indianapolis, Indiana 46227, United States
  • Medical Consultants, PC c/o Ball Cancer Center
    Muncie, Indiana 47303, United States
  • Northern Indiana Cancer Research Consortium
    South Bend, Indiana 46601, United States
  • Hope Center
    Terre Haute, Indiana 47802, United States
  • Medical Center of Vincennes
    Vincennes, Indiana 47591, United States
  • Iowa Cancer Care
    Cedar Rapids, Iowa 52403, United States
  • Mercy Medical Center, North Iowa
    Mason City, Iowa 50401, United States
  • Siouxland Hematology-Oncology Associates
    Sioux City, Iowa 51101, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • Hematology Oncology Life Center
    Alexandria, Louisiana 71301, United States
  • Maine Center for Cancer Medicine & Blood Disorders
    Scarborough, Maine 04074, United States
  • St. Agnes Health System
    Baltimore, Maryland 21229, United States
  • Maryland Oncology Hematology, P.A.
    Columbia, Maryland 21044, United States
  • Frederick Memorial Hospital
    Frederick, Maryland 21701, United States
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
  • Minnesota Oncology Hematology, P.A.
    Minneapolis, Minnesota 55404, United States
  • MN Cooperative Group Outreach Prg.
    Minneapolis, Minnesota 55407, United States
  • Park Nicollet Institute
    Saint Louis Park, Minnesota 55416, United States
  • Park Nicollet Institute
    St. Louis Park, Minnesota 55416, United States
  • Missouri Cancer Associates
    Columbia, Missouri 65201, United States
  • University of Missouri, Ellis Fischel Cancer Center
    Columbia, Missouri 65203, United States
  • St. Joseph Oncology, Inc.
    St. Joseph, Missouri 64507, United States
  • Nebraska Hematology-Oncology, PC
    Lincoln, Nebraska 68506, United States
  • Nebraska Methodist Hospital - Oncology Research Dept
    Omaha, Nebraska 68144, United States
  • Horizon's West Medical Group
    Scottsbluff, Nebraska 69361, United States
  • Comprehensive Cancer Centers of Nevada
    Las Vegas, Nevada 89109, United States
  • Nevada Cancer Institute
    Las Vegas, Nevada 89135, United States
  • UMDNJ-Newark
    Newark, New Jersey 07101, United States
  • The Valley Hospital
    Paramus, New Jersey 07652, United States
  • Overlook Oncology Center
    Summit, New Jersey 07901, United States
  • New Mexico Cancer Care Associates
    Sante Fe, New Mexico 87505, United States
  • SUNY Downstate Medical Center
    Brooklyn, New York 11203, United States
  • Hematology Oncology Associates of
    New City, New York 10956, United States
  • Memorial Sloan-Kett
    New York, New York 10021, United States
  • Interlakes Foundation Inc.
    Rochester, New York 14623, United States
  • University of Rochester Medical Center
    Rochester, New York 14642, United States
  • Staten Island Urological Research, PC
    Staten Island, New York 10304, United States
  • Raleigh Hematology Oncology Associates
    Cary, North Carolina 27511, United States
  • Carolina Cancer Management, Inc.
    Fayetteville, North Carolina 28304, United States
  • Piedmont Hematology Oncology Associates, PLLC
    Winston-Salem, North Carolina 27103, United States
  • Dakota Cancer Institute
    Fargo, North Dakota 58103, United States
  • Aultman Hospital
    Canton, Ohio 44710, United States
  • Gabrail Cancer Center
    Canton, Ohio 44718, United States
  • Oncology Hematology Care, Inc.
    Cincinnati, Ohio 45242, United States
  • The Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • Mid Ohio Oncology/Hematology, Inc.
    Columbus, Ohio 43213, United States
  • Dayton Oncology & Hematology, P.A.
    Kettering, Ohio 45409, United States
  • University of Oklahoma
    Oklahoma City, Oklahoma 73104, United States

Showing the first 100 of 223 sites across 9 countries. Choose a country and city above to see the rest.

07

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2006 and a completion of Nov 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 14, 2005
First posted
Jan 9, 2006
Start
Jan 2006
CompletionActual
Nov 2007
Last update
Nov 6, 2007
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 6, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00273338
Lead sponsor
Novacea
First posted
Jan 9, 2006
Start date
Jan 2006
Completion
Nov 2007
Last update
Nov 6, 2007

Study contacts

Howard I. Scher, MD
study chair · Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center
Kim N. Chi, M.D.
study chair · British Columbia Cancer Agency - Vancouver Centre
Ronald De-Wit, M.D.
study chair · Erasmus University Medical Center (Netherlands)
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Calcitriol · Docetaxel

Start the discussion